Given that LLT1 is upregulated in various cancers and transmits inhibitory signals to T cells, it is plausible that increased LLT1 expression on ALL cells may potentially cause T cell exhaustion and increased risk-of-relapse. This evidence concerns the gene CLEC2D and cancer.